OCTAVE - A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial...

Date 29 September 2019
Event ESMO 2019 Congress
Session Poster Display session 2
Topics Ovarian Cancer
Presenter Iain McNeish
Citation Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250
Authors I.A. McNeish1, V. Moreno2, G. Jayson3, P. Roxburgh4, M.P. Barretina Ginesta5, J. Garcia-Donas6, A. Anton Torres7, A. Michael8, R. Brown9, D. Krige10, J. Bendall11, G. Di Genova10, H. McElwaine-Johnn11
  • 1Department Of Surgery And Cancer, Imperial College London, W12 0NN - London/GB
  • 2Phase 1 Trials Unit, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 3Translational Research For The Medical Research, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 4Clinical Research Unit, Beatson West of Scotland Cancer Centre, G12 0YN - Glasgow/GB
  • 5Dept. Medical Oncology, ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), 17007 - Girona/ES
  • 6Genitourinary, Ginecologycal, Skin And Rare Tumors Unit, Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, 28050 - Madrid/ES
  • 7Oncology Department, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 8Urology, Royal Surrey County Hospital NHS Foundation Trust, GU2 7XX - Guildford/GB
  • 9Project Management, PsiOxus Therapeutics Ltd, OX14 3YS - Abingdon/GB
  • 10Clinical Assays, PsiOxus Therapeutics Ltd, OX14 3YS - Abingdon/GB
  • 11Clinial Development, PsiOxus Therapeutics Ltd, OX14 3YS - Abingdon/GB

Abstract

Background

Enadenotucirev (EnAd) is a tumor selective Ad11/Ad3 group B adenovirus that has demonstrated pre-clinical activity in a model of platinum-resistant ovarian cancer. Synergy has also been reported between oncolytic adenoviruses and microtubule manipulating drugs such as paclitaxel (Pxl). This study aims to establish the tolerability and preliminary efficacy of EnAd delivered in combination with Pxl. Here we present data from the intravenous (IV) dose expansion group.

Methods

Patients with platinum-resistant or refractory ovarian cancer received a minimum of two 28-days cycles of IV infusional EnAd (1x1012 viral particles) on days 1, 3 and 5, and IV Pxl (80mg/m2) on days 9, 16 and 23. Baseline and on-treatment biopsies were taken. Primary endpoint was safety and tolerability; additional endpoints included, response rate (RECISTv1.1/GCIG CA125 criteria) and duration of response.

Results

Twenty patients, median age 60.5 years (range 37-78) who had received a median of 4 prior lines of therapy (range 1-12) were enrolled. Adverse events reported from the combination of EnAd and Pxl were as previously described (for both agents individually), with ‘flu-like symptoms reported in the majority of patients following EnAd administration. Hematological changes including neutropenia, previously identified at higher doses of EnAd IV monotherapy, were reported at the dose level tested in this study population. Virus kinetics, cytokine and anti-virus antibody responses were consistent with previous results with EnAd. As of 03May19, Investigator-assessed ORR is 37.5% (6/16), with median DoR of 16 weeks (range 8-32). Reductions in CA125 broadly follow the pattern of tumor regression, with 36% (4/11) achieving response according to GCIG CA125 criteria. Disease control rate (RECIST CR, PR, SD) is 75% (12/16). To date, matched biopsies (N = 2) have been analysed for pharmacodynamic markers, providing preliminary evidence of increased CD8 T cell infiltration in on-treatment tumour biopsies.

Conclusions

The combination of EnAd and Pxl has manageable tolerability. Favorable disease control is noted in this recurrent platinum-resistant population, which is worthy of further investigation.

Clinical trial identification

2013-001276-38.

Editorial acknowledgement

Legal entity responsible for the study

PsiOxus Therapeutics Ltd.

Funding

PsiOxus Therapeutics Ltd.

Disclosure

R. Brown: Shareholder / Stockholder / Stock options, Full / Part-time employment: PsiOxus Therapeutics Ltds. D. Krige: Full / Part-time employment: PsiOxus Therapeutics Ltds. J. Bendall: Full / Part-time employment: PsiOxus Therapeutics Ltds. G. Di Genova: Full / Part-time employment: PsiOxus Therapeutics Ltds. H. McElwaine-Johnn: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: PsiOxus Therapeutics Ltds. All other authors have declared no conflicts of interest.